Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Neurotherapeutics
Erschienen in: Neurotherapeutics 4/2017

01.10.2017 | Review

Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis

verfasst von: Laura E. Baldassari, John W. Rose

Erschienen in: Neurotherapeutics | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Daclizumab is a humanized monoclonal antibody directed towards CD25, the alpha subunit of the high-affinity interleukin (IL)-2 receptor. Daclizumab exerts its effects via multiple mechanisms, including reduction of IL-2-mediated lymphocyte activation and upregulation of CD56–bright natural killer cells. Intravenous daclizumab (Zenapax™) was initially approved for prevention of rejection in renal transplant. In subsequent early testing, followed by larger-scale phase II and phase III trials, both intravenous and subcutaneous daclizumab have demonstrated clinical efficacy in the treatment of multiple sclerosis. The subcutaneous daclizumab prepared by high-yield process was utilized in the advanced phase II and phase III trials (SELECT and DECIDE). High-yield process daclizumab is now approved by the US Food and Drug Administration for relapsing-remitting multiple sclerosis, and is now formally termed daclizumab beta (DAC-beta; Zinbryta™). In this review, the early development of anti-IL-2 receptor alpha monoclonal antibodies and the properties of IL-2 and its receptor are discussed, and diverse mechanisms of action for daclizumab are presented. Results of the CHOICE, SELECT, and DECIDE clinical trials are discussed in detail. Adverse events observed in clinical trials included cutaneous reactions, liver enzyme elevations, infections, and autoimmune phenomena. DAC-beta is a monthly, patient-administered subcutaneous injection that requires enrollment in a safety monitoring (REMS) program for monthly liver function testing. Prescribers should be aware of the potential adverse events, as early recognition and management is important, particularly in cutaneous and hepatic reactions. Continued clinical experience with DAC-beta, including observations from the REMS program, will define its place in the armamentarium of immunotherapeutics for relapsing-remitting multiple sclerosis.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Therapeutic Monoclonal Antibodies: From the bench to the clinic. Hoboken, New Jersey: John Wiley & Sons, Inc; 2009.
2.
Martin R. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. Clin Immunol 2012;142(1):9-14.CrossRefPubMed
3.
4.
Sheridan JP, Robinson RR, Rose JW. Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis. Expert Rev Clin Pharmacol 2014;7(1):9-19.CrossRefPubMed
5.
Liao W, Lin JX, Leonard WJ. IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol 2011;23(5):598-604.CrossRefPubMedPubMedCentral
6.
Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol 2015;15(5):283-294.CrossRefPubMed
7.
Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol 2007;8(2):191-197.CrossRefPubMed
8.
Malek TR. The biology of interleukin-2. Ann Rev Immunol 2008;26:453-479.CrossRef
9.
Milo RS, Stüve O. Spotlight on daclizumab: its potential in the treatment of multiple sclerosis. Degen Neurol Neuromusc Dis 2016;6:95-109.
10.
Waldmann TA, Kozak RW, Tsudo M, Oh-ishi T, Bongiovanni KF, Goldman CK. IL-2 receptors in adult T-cell leukemia: a target for immunotherapy. Haematol Blood Transfus 1987;31:110-115.PubMed
11.
Waldmann TA, Longo DL, Leonard WJ, et al. Interleukin 2 receptor (Tac antigen) expression in HTLV-I-associated adult T-cell leukemia. Cancer Res 1985;45(9 Suppl.):4559s-4562s.PubMed
12.
Waldmann TA, O'Shea J. The use of antibodies against the IL-2 receptor in transplantation. Curr Opin Immunol 1998;10(5):507-512.CrossRefPubMed
13.
Waldmann TA. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol 2007;27(1):1-18.CrossRefPubMed
14.
Waldmann TA. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene 2007;26(25):3699-3703.CrossRefPubMed
15.
16.
Rose JW, Foley JF, Carlson NG. Monoclonal antibody treatments for multiple sclerosis. Curr Treat Options Neurol 2009;11(3):211-220.CrossRefPubMed
17.
Rose JW, Lorberboum-Galski H, Fitzgerald D, et al. Chimeric cytotoxin IL2-PE40 inhibits relapsing experimental allergic encephalomyelitis. J Neuroimmunol 1991;32(3):209-217.CrossRefPubMed
18.
Phillips SM, Bhopale MK, Constantinescu CS, et al. Effect of DAB(389)IL-2 immunotoxin on the course of experimental autoimmune encephalomyelitis in Lewis rats. J Neurol Sci 2007;263(1-2):59-69.CrossRefPubMed
19.
Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986;321(6069):522-525.CrossRefPubMed
20.
Queen C, Schneider WP, Selick HE, et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A 1989;86(24):10029-10033.CrossRefPubMedPubMedCentral
21.
Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998;338(3):161-165.CrossRefPubMed
22.
Nussenblatt RB, Fortin E, Schiffman RP et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A 1999;96(13):7462-7466.CrossRefPubMedPubMedCentral
23.
Nussenblatt RB, Peterson JS, Foster CS, et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 2005;112(5):764-770.CrossRefPubMed
24.
Nussenblatt RB, Thompson DJ, Li Z, et al. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun 2003;21(3):283-293.CrossRefPubMed
25.
Lehky TJ, Levin MC, Kubota R, et al. Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac. Ann Neurol 1998;44(6):942-947.CrossRefPubMed
26.
Bielekova B, Howard T, Packer AN, et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 2009;66(4):483-489.CrossRefPubMedPubMedCentral
27.
Rose JW, Watt HE, White AT, Carlson NG. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 2004;56(6):864-867.CrossRefPubMed
28.
Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007;69(8):785-789.CrossRefPubMed
29.
Rojas MA, Carlson NG, Miller TL, Rose JW. Long-term daclizumab therapy in relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord 2009;2(5):291-297.CrossRefPubMedPubMedCentral
30.
Oh J, Saidha S, Cortese I, et al. Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis. Neurology 2014;82(11):984-988.CrossRefPubMedPubMedCentral
31.
Pfender N, Martin R. Daclizumab (anti-CD25) in multiple sclerosis. Exp Neurol 2014;262 Pt A:44-51.CrossRefPubMed
32.
Wiendl HG, C.C. Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis. Nat Rev Neurol 2013;9(7):394-404.
33.
Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A 2006;103(15):5941-5946.CrossRefPubMedPubMedCentral
34.
Elkins J, Sheridan J, Amaravadi L, et al. CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS. Neurology 2015;2(2):e65.
35.
Chanvillard C, Jacolik RF, Infante-Duarte C, Nayak RC. The role of natural killer cells in multiple sclerosis and their therapeutic implications. Front Immunol 2013;4:63.CrossRefPubMedPubMedCentral
36.
Martin JF, Perry JS, Jakhete NR, Wang X, Bielekova B. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells. J Immunol 2010;185(2):1311-1320.CrossRefPubMedPubMedCentral
37.
Huss DJ, Mehta DS, Sharma A, et al. In vivo maintenance of human regulatory T cells during CD25 blockade. J Immunol 2015;194(1):84-92.CrossRefPubMed
38.
Oh U, Blevins G, Griffith CR et al. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch Neurol 2009;66(4):471-479.CrossRefPubMedPubMedCentral
39.
Jiang W, Chai NR, Maric D, Bielekova B. Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis. J Immunol 2011;187(2):781-790.CrossRefPubMedPubMedCentral
40.
Wuest SC, Edwan JH, Martin JF, et al. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med 2011;17(5):604-609.CrossRefPubMedPubMedCentral
41.
Schluns KS. Window of opportunity for daclizumab. Nat Med 2011;5: 545-547.CrossRef
42.
Yu A, Zhu L, Altman NH, Malek TR. A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity 2009;30(2):204-217.CrossRefPubMedPubMedCentral
43.
Snyder JT, Shen J, Azmi H, Hou J, Fowler DH, Ragheb JA. Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Th1/Th2 cytokine production. Blood 2007;109(12):5399-5406.CrossRefPubMedPubMedCentral
44.
Perry JS, Han S, Xu Q, et al. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci Transl Med 2012;4(145):145ra06.CrossRef
45.
Rose JW. Anti-CD25 immunotherapy: regulating the regulators. Sci Transl Med 2012;4(145):145fs25.CrossRefPubMed
46.
Gillard GO, Saenz SA, Huss DJ, Fontenot JD. Circulating innate lymphoid cells are unchanged in response to DAC HYP therapy. J Neuroimmunol 2016;294:41-45.CrossRefPubMed
47.
Wynn D, Kaufman M, Montalban X, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010;9(4):381-390.CrossRefPubMed
48.
Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet 2013;381(9884):2167-2175.CrossRefPubMed
49.
Giovannoni G, Gold R, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. Lancet Neurol 2014;13(5):472-481.CrossRefPubMed
50.
Gold R, Radue EW, Giovannoni G, et al. Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. BMC Neurol 2016;16:117.CrossRefPubMedPubMedCentral
51.
Kappos L, Wiendl H, Selmaj K, et al. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 2015;373(15):1418-1428.CrossRefPubMed
52.
Giovannoni G, Kappos L, Gold R, et al. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: an integrated analysis of clinical studies. Mult Scler Relat Disord 2016;9:36-46.CrossRefPubMed
53.
Cortese I, Ohayon J, Fenton K, et al. Cutaneous adverse events in multiple sclerosis patients treated with daclizumab. Neurology 2016;86(9):847-855.CrossRefPubMedPubMedCentral
54.
Mehta LR, Rose JW. Recurrent granuloma annulare during treatment with daclizumab. Mult Scler 2009;4:527-528.CrossRef
55.
Krueger JG, Kircik L, Hougeir F, et al. Cutaneous adverse events in the randomized, double-blind, active-comparator DECIDE study of daclizumab high-yield process versus intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis. Adv Ther 2016;33(7):1231-1245.CrossRefPubMedPubMedCentral
56.
57.
Gorman MP, Tillema JM, Ciliax AM, Guttmann CR, Chitnis T. Daclizumab use in patients with pediatric multiple sclerosis. Arch Neurol 2012;69(1):78-81.CrossRefPubMed
58.
Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362(5):402-415.CrossRefPubMed
59.
Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 2017;376(3):221-234.CrossRefPubMed
60.
Cohan S, Kappos L, Wiendl H, et al. Efficacy of daclizumab versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE. Mult Scler 2017 (in press).
61.
Rose JWG, G.; Wiendl, H.; Gold, R.; Havrdova, E.; Kappos, L.; Selmaj, K.W.; Zhao, J.; Riester, K.; Tsao L.C.; Greenberg, S.J. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2017;17:32-40.
62.
Othman AA, Tran JQ, Tang MT, Dutta S. Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration. Clin Pharmacokinet 2014;53(10):907-918.CrossRefPubMed
63.
Tran JQ, Othman AA, Mikulskis A, Wolstencroft P, Elkins J. Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis. Clin Pharmacol 2016;8:9-13.PubMedPubMedCentral
64.
Diao L, Hang Y, Othman AA, Nestorov I, Tran JQ. Population pharmacokinetics of daclizumab high-yield process in healthy volunteers and subjects with multiple sclerosis: analysis of phase I-III clinical trials. Clin Pharmacokineti 2016;55(8):943-955.CrossRef
65.
66.
Mitchell DA, Cui X, Schmittling RJ, et al. Monoclonal antibody blockade of IL-2 receptor alpha during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood 2011;118(11):3003-3012.CrossRefPubMedPubMedCentral
Metadaten
Titel
Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis
verfasst von
Laura E. Baldassari
John W. Rose
Publikationsdatum
01.10.2017
Verlag
Springer US
Erschienen in
Neurotherapeutics / Ausgabe 4/2017
Print ISSN: 1933-7213
Elektronische ISSN: 1878-7479
DOI
https://doi.org/10.1007/s13311-017-0553-8

Weitere Artikel der Ausgabe 4/2017

Neurotherapeutics 4/2017 Zur Ausgabe

Review

Cladribine to Treat Relapsing Forms of Multiple Sclerosis

Original Article

Tonabersat Prevents Inflammatory Damage in the Central Nervous System by Blocking Connexin43 Hemichannels

Commentary

Can a Neurosteroid Ameliorate Fragile X-Associated Tremor/Ataxia Syndrome?

Original Article

Fingolimod Exerts only Temporary Antiepileptogenic Effects but Longer-Lasting Positive Effects on Behavior in the WAG/Rij Rat Absence Epilepsy Model

Review

The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials

Review

The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise